In 2010, both the companies have signed a multi-year target validation agreement under which Tekmira offers Bristol-Myers Squibb with LNP formulations designed to validate the function of certain
The company expects to recruit around 85 patients in five clinical trial centers in the Poland. The Phase III trial intends to establish whether Multikine administered before current
Acelot’s new technology searches and mines directly in the space of molecules; something that has been thought of as too complex and slow in the past. Acelot said
TXA127 is a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow. The company will compare the time
As per the agreement, both the companies will jointly work and organize research for the discovery of DDS technology for RNAi therapeutics based on Samyang’s technology in three
Eisai Brazil will establish an initial infrastructure to support its operations debut into the Brazilian market. Eisai New Markets and ASEAN president Hajime Shimizu said the establishment of
The NBER researchers are expected to use the data from Medidata’s proprietary clinical trial cost databases PICAS and CROCAS, accessed through Medidata Grants Manager and Medidata CRO Contractor,
The company has posted loss from operations of $6.2m, compared to $3.26m for the comparable period in 2009. For the full year ended 31 December 2010, the company
Anavex will evaluate the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics in the Phase I trial. Anavex-2-73 represents a new class of wholly owned compounds that act through
The study result suggested that INC42 has reduced spleen size in patients with primary myelofibrosis (MF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF), when compared with
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.